Advertisement
UK markets closed
  • NIKKEI 225

    38,363.61
    -106.77 (-0.28%)
     
  • HANG SENG

    16,247.51
    +91.90 (+0.57%)
     
  • CRUDE OIL

    78.27
    +0.09 (+0.12%)
     
  • GOLD FUTURES

    2,035.80
    -4.00 (-0.20%)
     
  • DOW

    38,563.80
    -64.19 (-0.17%)
     
  • Bitcoin GBP

    41,417.51
    +424.14 (+1.03%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • NASDAQ Composite

    15,630.78
    -144.87 (-0.92%)
     
  • UK FTSE All Share

    4,206.04
    -7.91 (-0.19%)
     

Medigene AG to report full year 2022 financial results on March 29, 2023

Medigene AG
Medigene AG

Martinsried/Munich, March 15, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early-stage immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will report financial results and provide a corporate update for the fiscal year ended December 31, 2022 on Wednesday, March 29, 2023.

Following the release of the full year 2022 financial results on Medigene’s website, the company will host a conference call that same day at 3 p.m. CET (9 a.m. ET).

Full details for the conference call and webcast are as follows:

Date

March 29, 2023

Time

3:00 p.m. CET (9 a.m. ET)

U.S. Dial-in Number:

+1 877-451-6152

Int’l Dial-in Number:

+1 201-389-0879

Conference ID:

13736670

Webcast:

Join the live webcast here or at https://www.medigene.com/investors-media/reports-presentations

Please dial in 10 minutes ahead of time to ensure a timely start of the conference call.

Following the call, an archived webcast will be accessible on the Investors & Media section of the Medigene website: https://www.medigene.com/investors-media/reports-presentations

--- end of press release ---

About Medigene
Medigene AG (FSE: MDG1) is a leading immuno-oncology company dedicated to developing T-cell therapies to effectively eliminate cancer. Its end-to-end technology platform, built on multiple proprietary and exclusive product enhancement and product development technologies, allows Medigene to create best-in-class differentiated, T Cell Receptor engineered T cell (TCR-T) therapies for multiple solid tumor indications that are optimized for both safety and efficacy. This platform provides product candidates for both its in-house therapeutics pipeline and partnering. For more information, please visit www.medigene.com

Contacts
Medigene AG
Pamela Keck
Phone: +49 89 2000 3333 01
E-mail: investor@medigene.com

LifeSci Advisors

Sandya von der Weid
Phone: +41 78 680 05 38
E-mail: svonderweid@lifesciadvisors.com

In case you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com). We will then delete your address from our distribution list.